XML 37 R25.htm IDEA: XBRL DOCUMENT v3.19.2

Acquisitions - Additional Information (Detail) - USD ($)			3 Months Ended			6 Months Ended
	May 16, 2018	Jul. 19, 2017	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Business Combination Reverse Merger [Line Items]
Cash and cash equivalents		$ 9,900,000
Unamortized fair value of stock options		$ 3,700,000
Goodwill impairment charge			$ 0	$ 0	$ 5,200,000	$ 0	$ 5,187,519
Pear Tree Pharmaceuticals, Inc.
Business Combination Reverse Merger [Line Items]
Potential cash payments to acquire business	$ 75,000
Consideration amount	132,000
Research and Development Expense | Pear Tree Pharmaceuticals, Inc.
Business Combination Reverse Merger [Line Items]
Transaction costs	$ 452,000

X

- Definition

Business combination reverse merger.

+ References

No definition available.

+ Details

Name:	dare_BusinessCombinationReverseMergerLineItems
Namespace Prefix:	dare_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.

+ References

No definition available.

+ Details

Name:	dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Business combination reverses merger stock purchase transaction cost.

+ References

No definition available.

+ Details

Name:	dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Business combination reverse merger unamortized fair value of stock options.

+ References

No definition available.

+ Details

Name:	dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Potential Cash Payments To Acquire Business

+ References

No definition available.

+ Details

Name:	dare_PotentialCashPaymentsToAcquireBusiness
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266

+ Details

Name:	us-gaap_GoodwillImpairmentLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=dare_PearTreePharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: